ORAL T-8
Oral Testosterone Male Contraceptive
- User: Male
- Hormonal: Hormonal
-
Delivery type:
- Oral
-
Intended Duration:
- Undetermined
- Development Stage: Phase I
- Developer(s)/researcher(s): University of Washington, GlaxoSmithKline, NICHD
Details
- API: Testosterone
- Target: Androgen Receptor
-
Mechanism of Action:
- Reduced Sperm Production
- Regimen: 3 Pills/Day
- MPT: Not Potential MPT
- Promising Attributes: Not Established - Limited Public Information
Product Status
No Indication of Development after 2013
History
Phase I trial of 12 participants initiated in 2010. 8/12 participants experienced non-serious adverse events, though not all adverse events were associated with the drug.